Issued patents provide intellectual property protection for clinical candidates, AP-SA02 and AP-PA02

Gainers GlucoTrack (NASDAQ:GCTK) stock moved upwards by 90.6% to $3.87 during Wednesday's after

Armata Pharmaceuticals Inc. (AMEX:ARMP) shares are trading lower on Wednesday as traders digest addi

Armata Pharmaceuticals technical headwinds overshadow a $3.7 million Department of Defense grant fun

HC Wainwright & Co. analyst Joseph Pantginis reiterates Armata Pharmaceuticals (AMEX:ARMP) wi

Importantly, the $3.7 million represents the first funding received specifically for Phase 3 executi

Initial Phase 3-focused funding to support advancement of AP-SA02 in complicated Staphylococcus aure

Controlled manufacturing reproducibly maintains defined genetic diversity across AP-SA02 clinical dr

Gainers Circle8 Group (NASDAQ:CIRC) stock moved upwards by 14.6% to $0.57 during Monday's after

Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) stock moved upwards by 44.6% to $2.4 during Monday&

Designation for adjunct treatment of complicated bacteremia caused by methicillin-sensitive S. aureu

Designation is driven by compelling Phase 2 clinical data in patients with complicated Staphylococcu

LOS ANGELES, Sept. 10, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Arm

LOS ANGELES, Sept. 3, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Arma

Armata Pharmaceuticals (AMEX:ARMP) reported quarterly losses of $(0.27) per share which beat the ana

LOS ANGELES, Aug. 12, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Arma

Armata Pharmaceuticals (ARMP) witnessed a jump in share price last session on above-average trading

ARMP stock jumps 10% as Armata Pharmaceuticals prepares its AP-SA02 multi-phage candidate for a pivo

Executive Leadership UpdateArmata also announced the promotion of David House to Chief Financial Off

FDA submissions address all feedback on clinical, CMC, and regulatory topics from the End-of-Phase 2

FDA submissions address all feedback on clinical, CMC, and regulatory topics from the End-of-Phase 2

Fulfills important regulatory milestone for AP-SA02 on the path toward a future BLA and supports exp

Fulfills important regulatory milestone for AP-SA02 on the path toward a future BLA and supports exp

Supports Phase 3 readiness of AP-SA02Non-dilutive DoD funding totals $28.7M to dateLOS ANGELES, June

Supports Phase 3 readiness of AP-SA02 Non-dilutive DoD funding totals $28.7M to date LOS ANGELES, Ju

Armata Pharmaceuticals (AMEX:ARMP) reported quarterly losses of $(3.16) per share which missed the a

Entered into secured credit agreement with Innoviva for $25 million maturing in 2029 LOS ANGELES, Ma

Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a late clinica

Enables more frequent FDA engagement, rolling Biologic License Application review, and the potential

The publication, titled, "Structural atlas of Pakpunavirus P7-1 reveals determinants of virion s

Describes structure of phage P7-1, included in Armata's Pseudomonas aeruginosa phage cocktail, AP-PA

LOS ANGELES, April 27, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Arm

U.S. stock futures down, Zenas Biopharma shares fall 9.5% in pre-market trading due to pricing of pu

Armata Pharmaceuticals (AMEX:ARMP) reported quarterly losses of $(3.43) per share which missed the a

LOS ANGELES, March 25, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Arm

Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a late clinica

LOS ANGELES, March 19, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Arm

HC Wainwright & Co. analyst Joseph Pantginis maintains Armata Pharmaceuticals (AMEX:ARMP) wit

Intravenous use as a QIDP for adjunct treatment of complicated bacteremia caused by Staphylococcus a

FDA agreed that data from the Phase 2a diSArm study support advancement of AP-SA02 to a Phase 3study

Jones Trading analyst Debanjana Chatterjee initiates coverage on Armata Pharmaceuticals (AMEX:ARM

Armata Pharmaceuticals (AMEX:ARMP) reported quarterly losses of $(0.74) per share which missed the a

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a cl